FLGT - CIK 0001674930
Fulgent Genetics, Inc. (FLGT) reported net income of -$60.51M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$60.51M | -41.7% |
| FY 2024 | -$42.71M | +74.6% |
| FY 2023 | -$167.82M | -217.0% |
| FY 2022 | $143.40M | -71.7% |
| FY 2021 | $507.36M | +136.7% |
| FY 2020 | $214.31M | +52243.6% |
| FY 2019 | -$411.00K | +92.7% |
| FY 2018 | -$5.61M | -123.4% |
| FY 2017 |
Fulgent Genetics, Inc. (FLGT) reported net income of -$60.51M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Fulgent Genetics, Inc.'s net income declined from -$4.28M to -$60.51M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$2.51M |
| +53.1% |
| FY 2016 | -$5.35M | +35.7% |
| FY 2015 | -$8.31M | -94.1% |
| FY 2014 | -$4.28M | - |